Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $5.69 USD
Change Today -0.19 / -3.23%
Volume 170.5K
VBLT On Other Exchanges
As of 8:10 PM 11/25/15 All times are local (Market data is delayed by at least 15 minutes).

vascular biogenics ltd (VBLT) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/27/15 - $17.02
52 Week Low
03/13/15 - $3.09
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

vascular biogenics ltd (VBLT) Related Bloomberg News

View More Bloomberg News

vascular biogenics ltd (VBLT) Related Businessweek News

No Related Businessweek News Found

vascular biogenics ltd (VBLT) Details

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer and immune-inflammatory diseases in Israel. Its lead product candidates include VB-111, a gene-based biologic that has completed Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; in Phase II clinical trials to treat thyroid cancer; and in Phase I/II clinical trials for the treatment of ovarian cancer. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was founded in 2000 and is headquartered in Or Yehuda, Israel.

33 Employees
Last Reported Date: 11/12/15
Founded in 2000

vascular biogenics ltd (VBLT) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

vascular biogenics ltd (VBLT) Key Developments

VBL Therapeutics Announces Significant Improvement of 12 Month Overall Survival with VB-111 Compared to Pooled Data from Four Avastin Studies at the Annual Meeting of the Society for Neuro-Oncology

VBL Therapeutics announced the presentation of new data on its lead oncology product VB-111, a first-in-class, targeted, anti-angiogenic gene-therapy agent with applicability for multiple solid tumor indications, at the 20th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO), being held in San Antonio, Texas, showing significant improvement of 12 month overall survival (OS) with VB-111 in recurrent Glioblastoma multiforme (rGBM) compared to pooled data from four different Avastin studies. VB-111 is being featured in a poster presentation at SNO as well as in a satellite symposium sponsored by the company, both taking place November 20. New data are being presented that compare the 12 month overall survival achieved with VB-111 in rGBM to the results from four different trials of bevacizumab (Avastin) in this disease setting (n=233). In the recently completed Phase 2 study, the overall survival rate for patients treated with VB-111 in combination with bevacizumab upon disease progression (continuous exposure cohort) was 57% at 12 months. This compares with an overall 12 month survival of 28% (range 16% to 38%) in the pooled data from the 4 Avastin studies (p = 0.007). The company's pivotal Phase 3 GLOBE study in rGBM which started in August 2015, is comparing VB-111 in combination with bevacizumab to bevacizumab alone and is recruiting about 252 patients in the US, Canada and Israel. The study is proceeding under a Special Protocol Assessment (SPA) granted by the FDA, with full endorsement by the Canadian Brain Tumor Consortium (CBTC). VB-111 has received orphan drug designation in the United States and Europe and was granted Fast Track designation by the FDA for prolongation of survival in patients with glioblastoma that has recurred following treatment with standard chemotherapy and radiation.

Vascular Biogenics Ltd. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015

Vascular Biogenics Ltd. reported unaudited earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, the company reported operating loss was $5,735,000 against $3,389,000 a year ago. Comprehensive loss was $5,787,000 against $3,515,000 a year ago. Basic and diluted per ordinary share was $0.29 against $2.45 a year ago. For the nine months, the company reported operating loss was $11,687,000 against $9,755,000 a year ago. Comprehensive loss was $11,728,000 against $12,272,000 a year ago. Basic and diluted per ordinary share was $0.59 against $9.98 a year ago. Net cash used in operating activities was $9,029,000 against $11,216,000 a year ago. Purchases of property and equipment were $41,000 against $49,000 a year ago.

Vascular Biogenics Ltd. to Report Q3, 2015 Results on Nov 12, 2015

Vascular Biogenics Ltd. announced that they will report Q3, 2015 results on Nov 12, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VBLT:US $5.69 USD -0.19

VBLT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VBLT.
View Industry Companies

Industry Analysis


Industry Average

Valuation VBLT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact VASCULAR BIOGENICS LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at